Search

everythinglearnresearchcommunity

for

Search:↓

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

A transwoman developed a brain tumor after nine years of hormone therapy, suggesting a possible link between the treatment and tumor development.

A boy with early puberty and laughing seizures was treated, stopping seizures and slowing puberty.

Leuprolide effectively reduces hair growth in hirsute women at higher doses.

Leuprolide plus estrogen is more effective than oral contraceptives for reducing hirsutism.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Leuprolide may better manage cholesterol and blood pressure in PCOS than spironolactone.

Letrozole combined with Cabergoline improves ovulation and pregnancy rates in women with PCOS and high prolactin levels compared to Letrozole alone.

Deslorelin effectively treats hair loss in neutered ferrets by reducing hormone levels.

Nafarelin may effectively treat excessive hair growth in women by reducing certain hormone levels.

Early diagnosis and treatment with Leuprolide are key for children with precocious puberty.

Provenge extends prostate cancer survival by about 4 months.

Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.

Deslorelin implant successfully regrew hair in a female Pomeranian with alopecia X.

Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.

The conclusion is that removing both ovaries is the best treatment for excess male hormones in postmenopausal women, with medication as another option, and managing insulin resistance is important for diagnosis and treatment.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

High testosterone levels can harm fertility by disrupting the LIF signaling pathway in the uterus.

Buserelin safely and effectively suppresses early puberty, potentially improving final height.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.

The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

Some common medications can harm male fertility, but many effects can be reversed.